Standard BioTools Inc Dossier
Qualitative Analysis
Business overview
Standard BioTools Inc. (formerly Fluidigm Corporation) is a life science tools provider that develops, manufactures, and sells analytical technologies for biomedical researchers. The company's core offerings include mass cytometry systems (such as CyTOF XT and Hyperion XTi) for spatial proteomics and flow cytometry, alongside microfluidics-based genomic analysis instruments (such as the Biomark X9 System) and associated consumables. Standard BioTools serves academic research institutions, translational research and medical centers, and biopharmaceutical companies globally. In a major strategic shift announced on June 8, 2026, Standard BioTools entered into a definitive agreement to merge with Treeline Biosciences in an all-stock transaction. Upon completion, the combined company will operate under the Treeline Biosciences name (ticker: TRLN) and focus on oncology therapeutics, while exploring strategic options, including divestitures, for its legacy mass cytometry and microfluidics tools businesses.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A definitive merger agreement to combine with Treeline Biosciences in an all-stock transaction, transitioning the company into a public clinical-stage oncology and immunology drug developer.
Expected impact: Creates a combined entity trading under 'TRLN' with over $900 million in cash, funding operations into 2029, while legacy tools businesses are slated for divestiture.
Strategic sale of the SomaLogic business (including SomaScan Assay Services, Authorized Sites, and KREX) to Illumina, Inc.
Expected impact: Generated $350 million in upfront cash (with up to $75 million in potential earnouts and a 10-year 2% royalty on SOMAmer-based NGS kits), significantly strengthening the balance sheet to approximately $550 million in cash.
Streamlining the organization, optimizing workflows, and reducing manufacturing lead times to improve gross margins and lower operating expenses.
Expected impact: Fully operationalized over $40 million in annualized cost savings in 2025, reducing Q1 2026 operating expenses by 37% year-over-year and narrowing the adjusted EBITDA loss to $3.1 million, supporting the path to positive adjusted EBITDA exiting 2026.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Following the sale of SomaLogic to Illumina, Standard BioTools retains a 2% royalty on net revenues from sales of SOMAmer-based NGS library prep kits for 10 years and a co-exclusive license for Single SOMAmer commercialization in singleplex affinity assays.
Terms: Upfront payment of $350 million in cash, up to $75 million in earnout payments ($25 million based on 2025 performance and $50 million based on 2026 performance), and a 2% royalty on net revenues of SOMAmer-based NGS library prep kits.